Journals / Archives of Clinical and Experimental Medicine / 2020 / Cilt: 5 - Sayı: 3

Clinical correlates of treatment adherence and insight in patients with schizophrenia

Pages
95–99
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further research is needed to clarify clinical associations of the treatment adherence and insight level in patients with schizophrenia.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The aim of this study was to assess clinical correlates of the treatment adherence and insight in patients with schizophrenia.Methods: That cross-sectional study included 229 outpatients with schizophrenia who were admitted to the Psychiatry Outpatient Clinic of Health Sciences University Dışkapı Yıldırım Beyazıt Training and Research Hospital.
📊
Key Findings & Data:Therefore, psychotherapeutic interventions should be implemented to increase treatment adherence and insight in schizophrenia even if the psychotic symptoms show resistance.
💡
Conclusion & Impact:Further research is needed to clarify clinical associations of the treatment adherence and insight level in patients with schizophrenia.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: The aim of this study was to assess clinical correlates of the treatment adherence and insight in patients with schizophrenia.Methods: That cross-sectional study included 229 outpatients with schizophrenia who were admitted to the Psychiatry Outpatient Clinic of Health Sciences University Dışkapı Yıldırım Beyazıt Training and Research Hospital. All participants were administered a socio-demographic form, Morisky Medication AdherenceQuestionnaire, Schedule for Assessing the three components of insight, Brief Psychiatric Rating Scale, Positive and Negative Symptoms Rating Scale, Calgary Depression Scale for Schizophrenia, and Global Assessment of Functioning Scale. Collected data were analyzed with descriptive statistics, Pearson Correlation Analysis, and logistic regression analysis.Results: Poor treatment adherence was associated with male gender, lower insight level, more severe psychotic symptoms, and lower functionality level. The insight score was negatively correlated with the severity of psychotic symptoms, duration of the disorder, and mean antipsychotic dose; but positively correlated with advanced age of onset, and higher functionality level. The logistic regression analysis revealed that functionality level was more predictive on poor medication adherence.Conclusion: Poor treatment adherence and lower insight level were closely associated with more severe clinical symptoms and lower functionality level. It was noteworthy that adherence and insight levels both showed a high predictivity for wellbeing of the patients. Therefore, psychotherapeutic interventions should be implemented to increase treatment adherence and insight in schizophrenia even if the psychotic symptoms show resistance. Further research is needed to clarify clinical associations of the treatment adherence and insight level in patients with schizophrenia.

🔖

Cite This Article

KARADAĞ, H., ÖRSEL, S., KOKURCAN, A., DOĞU, S. E., ERDİ, F. (2022). Clinical correlates of treatment adherence and insight in patients with schizophrenia. Archives of Clinical and Experimental Medicine, Cilt: 5 - Sayı: 3, 95–99. https://ajindex.com/articles/447827

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. García-Cabeza I, Díaz-Caneja CM, Ovejero M, de Portugal E. Adherence, insight and disability in paranoid schizophrenia. Psychiatry Res. 2018;270:274-80
  2. Modanloo M. The challenge of increasing adherence in schizophrenia: Focusing future research on changing attitudes of patients. Asian J Psychiatr. 2018;36:28
  3. Xu DR, Gong W, Gloyd S, Caine ED, Simoni J, Hughes JP, et al. Measuring adherence to antipsychotic medications for schizophrenia: Concordance and validity among a community sample in rural China. Schizophr Res. 2018;201:307-14
  4. Ogawa Y, Fukuhara K, Tanaka H, Nagata Y, Ishimaru D, Nishikawa T. Insight Into Illness and Defense Styles in Schizophrenia. J Nerv Ment Dis. 2019;207:815-19
  5. Settem VVJ, Karanadi H, Praharaj SK. Cognitive deficits, depressive symptoms, insight, and medication adherence in remitted patients with schizophrenia. Indian J Psychiatry 2019;61:335-41
  6. Browne J, Nagendra A, Kurtz M, Berry K, Penn DL. The relationship between the therapeutic alliance and client variables in individual treatment for schizophrenia spectrum disorders and early psychosis: Narrative review. Clin Psychol Rev. 2019;71:51-62
  7. Belvederi Murri M, Amore M. The Multiple Dimensions of Insight in Schizophrenia-Spectrum Disorders. Schizophr Bull. 2019;45:277-83
  8. Tessier A, Boyer L, Husky M, Baylé F, Llorca PM, Misdrahi D. Medication adherence in schizophrenia: The role of insight, therapeutic alliance and perceived trauma associated with psychiatric care. Psychiatry Res. 2017;257:315-21
  9. Kane JM, Agid O, Baldwin ML, Howes O, Lindenmayer JP, Marder S, et al. Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. J Clin Psychiatry 2019;80. pii: 18com12123. doi: 10.4088/JCP.18com12123
  10. Arraras JI, Ibañez B, Pereda N, Iribarren S, Basterra I. The association of clinical insight and depression with quality of life in schizophrenia. Psychiatry Res. 2019;279:350-52
  11. Dondé C, Senn M, Eche J, Kallel L, Saoud M, Brunelin J. Wellinformed but not aware: The P.A.C.T.® psychoeducation program for schizophrenia improves knowledge about, but not insight into, the illness. Asian J Psychiatr. 2019;46:15-8
  12. American Psychiatric Association. Schizophrenia spectrum and other psychotic disorders. In: Carpenter WT, editor. Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA:American Psychiatric Association; 2013.p.87-123
  13. Overall JE, Gorham DR. The brief psychiatric rating scale (BPR